Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for symptom relief in Low-Risk blood cancer patients

NCT ID NCT04644211

First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 20 times

Summary

This study tests whether the drug ruxolitinib can reduce symptoms like fatigue, itching, and night sweats in people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV) who have significant symptom burden. About 60 adults will take ruxolitinib and be monitored for symptom improvement and blood count changes. The goal is to improve quality of life, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth-Israel Deaconess Medical Center

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General North Shore Cancer Center

    RECRUITING

    Danvers, Massachusetts, 01923, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.